Latest Delcath Systems News & Updates

See the latest news and media coverage for Delcath. We track all announcements, press releases, and industry mentions in real time, all in one place.

Delcath Systems (Delcath)

Interventional oncology company focused on liver cancer treatments

delcath.com

Headquarters: New York, United States
Founded year: 1987
Company type: Public company
Number of employees: 150–200
Industry: Biotechnology & Medical Research

Last updated October 6

Latest news about Delcath Systems (Delcath)

In short: Delcath delivered strong 2026 revenue growth, raised guidance to $104-108M, and advanced liver-directed oncology trials.

Company announcements

August 17 Delcath

Delcath reports Q2 2026 financial highlights

Revenue reached $29.1 million with 30% volume growth. The company increased full-year guidance to $104-108 million and initiated a Phase 2 trial.

August 6 Delcath

Delcath Systems announces Q2 2026 results and raises guidance

Total revenue reached $29.1 million, up from $24.2 million year-over-year. The company increased its 2026 revenue guidance to $104-$108 million and reported cash and investments of $95.9 million.

May 7 Delcath

Delcath Systems reports Q1 2026 financial results

Revenue reaches $25M, up from $19.8M. Issues $100M 2026 guidance. Highlights HEPZATO growth and CHOPIN trial publication.

April 23 Delcath

Delcath Systems announces Q1 2026 earnings call

The call is scheduled for May 7, 2026, at 8:30 AM ET to discuss results for the quarter ended March 31, 2026. Dial-in numbers and webcast are provided.

Media coverage

October 6 Benzinga

Delcath Systems Q2 2026 Earnings Call Transcript - Delcath Systems (NASDAQ:DCTH) - Benzinga

Delcath Systems (NASDAQ:DCTH) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time...

August 6 Seeking Alpha

Delcath raises 2026 revenue guidance to $104M-$108M amid plans for 37 active centers by year-end (NASDAQ:DCTH)

Delcath Systems (DCTH) Q2 2026 earnings call: raised revenue guidance to $104M-$108M, expanding...

August 4 GuruFocus

Delcath Systems Reports Second Quarter 2026 Results and Business

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of...

June 29 StockHouse

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT(TM) in Metastatic Uveal Melanoma Subgroups

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the...

Never miss news about Delcath

Track Delcath and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Delcath competitors & trending companies

Browse news for competitors to Delcath and other trending companies.